Condition: Acute Myeloid Leukemia Refractory · Myelodysplastic Syndrome Acute Myeloid Leukemia · Myelodysplastic Syndrome With Excess Blasts · Sponsor: Apollo Therapeutics Ltd
This is an open-label, Phase 1 study to determine the safety, tolerability, and efficacy of APL-4098 alone, and in combination with azacitidine, and in combination with azacitidine plus venetoclax for the treatment of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS)/AML and MDS-excess blasts (EB).
This description comes directly from the study's public registry record.
Apollo Therapeutics · 781-479-2267 · AP30@apollotx.com
Always discuss trial participation with your own doctor first.
| Monash Health | Clayton, Victoria, Australia | Recruiting |
| St. Vincent's Hospital Melbourne | Fitzroy, Victoria, Australia | Recruiting |
| The Alfred Hospital | Melbourne, Victoria, Australia | Recruiting |
| Hollywood Private Hospital | Nedlands, Western Australia, Australia | Active Not Recruiting |
| Royal Perth Hospital | Perth, Western Australia, Australia | Recruiting |
| University Hospital of Wales | Cardiff, United Kingdom | Recruiting |
| Beatson West of Scotland Cancer Centre | Glasgow, United Kingdom | Recruiting |
| The Royal Marsden Hospital | London, United Kingdom | Recruiting |
| Sarah Cannon Research Institute UK | London, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06372717